89bio
CA - San Francisco
BiotechnologyFocus: Liver Treatments
89bio is a life sciences company focused on Liver Treatments.
Oncology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
BIO89-100
NASH - Nonalcoholic SteatohepatitisClinical Trials (1)
NCT05022693PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
Phase 1Pegozafermin
NASHClinical Trials (1)
NCT04048135A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Phase 1/2BIO89-100
NASH - Nonalcoholic SteatohepatitisClinical Trials (1)
NCT04929483Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
Phase 2Pegozafermin
Severe HypertriglyceridemiaClinical Trials (1)
NCT04541186Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
Phase 2Phase 3
Clinical Trials (1)
NCT06419374A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Phase 3Pegozafermin
Severe HypertriglyceridemiaClinical Trials (1)
NCT05852431To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Phase 3Phase 3
Clinical Trials (1)
NCT06318169A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 7 clinical trials
Top TAs: Infectious Diseases, Metabolic Diseases
Publications: 14 in PubMed